FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

On February 22, 2017, the U.S. Food and Drug Administration (FDA) granted approval for the use of lenalidomide as maintenance therapy after autologous hematopoietic stem cell transplantation (auto‐HSCT) for patients with multiple myeloma. The approval was based on evidence from two randomized, blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulte, Elizabeth Dianne, Dmytrijuk, Andrew, Nie, Lei, Goldberg, Kirsten B., McKee, Amy E., Farrell, Ann T., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067941/
https://www.ncbi.nlm.nih.gov/pubmed/29438096
http://dx.doi.org/10.1634/theoncologist.2017-0440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067941/
https://www.ncbi.nlm.nih.gov/pubmed/29438096
http://dx.doi.org/10.1634/theoncologist.2017-0440

Ejemplares similares